{
    "organizations": [],
    "uuid": "ebd38d1b7ce24ea854be8cca1e71326ab1ebfa9a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-asit-biotech-fy-net-loss-narrows-t/brief-asit-biotech-fy-net-loss-narrows-to-12-0-million-euros-idUSL8N1Q20MZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Asit Biotech FY Net Loss Narrows To ‍​12.0 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - ASIT BIOTECH SA:\n* FY OPERATING LOSS EUR 12.0 MILLION VERSUS LOSS OF EUR 12.3 MILLION YEAR AGO\n* CLINICAL AND RESEARCH AND DEVELOPMENT PROGRAMS ON TRACK WITH MULTIPLE DEVELOPMENT MILESTONES EXPECTED IN 2018‍​\n* CASH POSITION AT END-2017 OF €2.13 MILLION‍​\n* REDUCTION IN OPERATING EXPENSES IN LINE WITH THE COMPANY’S EXPECTATIONS‍​\n* FY NET LOSS EUR ‍​12.0 MILLION VERSUS LOSS OF EUR 12.3 MILLION YEAR AGO\n* 2ND PHASE III GP-ASIT+ TRIAL IN EUROPE IN ADULTS WITH SITE SELECTION IN Q4 2018\n* FIRST-PATIENT FIRST-VISIT FOR GP-ASIT+ IN Q1 2019‍​ III Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-12T14:26:00.000+02:00",
    "crawled": "2018-02-13T15:32:09.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "asit",
        "biotech",
        "sa",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "clinical",
        "research",
        "development",
        "program",
        "track",
        "multiple",
        "development",
        "milestone",
        "expected",
        "cash",
        "position",
        "reduction",
        "operating",
        "expense",
        "line",
        "company",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "2nd",
        "phase",
        "iii",
        "trial",
        "europe",
        "adult",
        "site",
        "selection",
        "q4",
        "q1",
        "iii",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}